Results from a phase III clinical study published online in the European Journal of Neurology Early View showed that about half of all people with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to standard anti-spasticity therapy, find that adding Sativex Oromucosal Spray (delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)), to their existing medication can improve the debilitating symptoms of spasticity associated with MS.
The primary efficacy endpoint was the change in a validated, 10 point (0-10) self-reported spasticity numerical rating scale (NRS) from the point of randomisation to the end of the treatment. Sativex was shown to provide significant improvement, compared to placebo, in the NRS spasticity score, spasm frequency and sleep disturbance related to spasticity.
An international team of editors is busy daily to provide readers with exclusive news articles and featured stories through the Sensi Seeds blog. Personal Note is a column in which they share their personal motivations and discoveries. This will enable you to get to know the team better, and vice versa, since - as always - your reactions and comments are very welcome. Read this months column »